Variable | Â | Univariate model | Multivariate model 1 | Multivariate model 2 |
---|---|---|---|---|
 |  | Odds ratio, 95% CI (P-value) | Odds ratio, 95% CI (P-value) | Odds ratio, 95% CI (P-value) |
Age (continuous) | Â | 1.04, (0.98; 1.09) 0.184 | 1.08, (1.01; 1.15) 0.034 | 1.07 (1.01; 1.14) 0.029 |
Age (≤ 34 = 0, >34 = 1) |  | 1.20, (0.56; 2.60) 0.637 |  |  |
Gender (male = 0, female = 1) | Â | 0.55, (0.19; 1.56) 0.260 | 0.52, (0.14; 1.99) 0.341 | Â |
WHO stage (1&2 = 0, 3&4 = 1) | Â | 0.38, (0.13; 1.08) 0.068 | 0.61, (0.17; 2.15) 0.441 | Â |
Baseline CD4 count cells/mm3 (>50 = 0, ≤ 50 = 1) |  | 0.42, (0.15; 1.17) 0.098 | 0.93, (0.25; 3.41) 0.910 |  |
Baseline viral load log copies/ml (≤ 5 = 0, >5 = 1) |  | 0.24, (0.10; 0.59) 0.002 | 0.48, (0.14; 1.65) 0.245 | 0.22, (0.08; 0.60) 0.003 |
Pre-HAART PHS score (continuous) | Â | 1.14 (1.07; 1.21) <0.001 | 1.16 (1.08; 1.24) <0.001 | 1.15 (1.08; 1.23) <0.001 |
Week 48 CD4 count cells/mm3 (<250 = 0, ≥ 250 = 1) |  | 0.63, (0.29; 1.37) 0.245 |  |  |
Week 48 CD4 count cells/mm3 | <200 | 1 | Â | Â |
 | 200–350 | 0.62, (0.25; 1.51) 0.29 |  |  |
 | 350–500 | 0.67, (0.22; 2.07) 0.483 |  |  |
 | ≥ 500 | 0.42, (0.08; 2.21) 0.309 |  |  |
Week 48 viral load copies/ml (<50 = 0, ≥ 50 = 1) |  | 0.96, (0.37; 2.48) 0.935 |  |  |
Week 48 viral load copies/ml | <50 | 1 | Â | Â |
 | 50–399 | 0.39, (0.08; 1.79) 0.224 |  |  |
 | 400–4999 | 1.10, (0.11; 11.00) 0.936 |  |  |
 | ≥ 5000 | 3.30, (0.77; 14.07) 0.107 |  |  |
Week 48 log viral load log copies/ml (<1.69 = 0, ≥ 1.69 = 1) |  | 0.96, (0.37; 2.48) 0.935 |  |  |
Week 48 log viral load log copies/ml | <1.69 | 1 | Â | Â |
 | 1.69–2.59 | 0.58, (0.16; 2.14) 0.414 |  |  |
 | 2.60–3.69 | 1.10, (0.11; 11.00) 0.936 |  |  |
 | ≥ 3.69 | 2.47, (0.51; 11.74) 0.225 |  |  |
Δ CD4 count cells/mm3 |  | 0.995, (0.991; 0.999) 0.010 | 0.998, (0.993; 1.003) 0.420 |  |
Δ log viral load log copies/ml |  | 0.58, (0.37; 0.90) 0.015 | 0.66, (0.36; 1.27) 0.209 |  |